Carregant...

Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review

Immune checkpoint inhibitors (ICIs) belong to a new group of anticancer drugs targeting T-cell proteins involved in the activation of immune response toward malignancies. Their introduction into clinical practice was a milestone in modern cancer treatment. However, the significant advantage of ICIs...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Maria Stelmachowska-Banaś, Izabella Czajka-Oraniec
Format: Artigo
Idioma:Inglês
Publicat: Bioscientifica 2020-10-01
Col·lecció:Endocrine Connections
Matèries:
Accés en línia:https://ec.bioscientifica.com/view/journals/ec/9/10/EC-20-0342.xml
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!